General MedicationsINJECTIONGeneric
ROCEPHIN
CEFTRIAXONE SODIUM
Standard Dose
EQ 250MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ROCEPHIN is listed in Drugs@FDA under application 063239 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFTRIAXONE SODIUM Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/VIAL Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2015-06-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview ROCEPHIN is listed in Drugs@FDA under application 063239 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CEFTRIAXONE SODIUM Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/VIAL Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2015-06-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.